Infections, Cytomegalovirus
3
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
+ 2 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
ViiV HealthcareNC - Durham
1 program1
GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903APhase 1Vaccine
GSKLONDON, United Kingdom
1 programGSK Biologicals' Recombinant CMV gB Vaccine GSK1492903APHASE_1Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
MSDLetermovir 240 mg Oral Tablet
GSKGSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
Clinical Trials (2)
Total enrollment: 130 patients across 2 trials
Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.
Start: Oct 2023Est. completion: Apr 202790 patients
Phase 2Not Yet Recruiting
Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects
Start: Feb 2007Est. completion: Aug 200840 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
Vaccine is the dominant modality (100% of programs)
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.